About Us Our BioBank Platform Technology Our Drug Programmes News Contact us Analysts INVESTORS NEWS The following analysts cover Synairgen *Joint Broker to Synairgen FinnCap* Mark Brewer 020 7220 0556 mbrewer@finncap.com Numis* Dr Paul Cuddon E: p.cuddon@numis.com Tel: +44 (0)207 260 1000 Dr Stefan Hamill E: s.hamill@numis.com P: +44 (0)207 260 1000 Synairgen plc Registered in England and Wales No. 5233429 Registered office Mailpoint 810, Level F, South Block, Southampton General Hospital, Tremona Road, Southampton, SO16 6YD, UK

About Us Our BioBank Platform Technology Our Drug Programmes News Contact us Research Capabilities INVESTORS NEWS Synairgen has specialised scientific research and clinical teams dedicated to drug discovery and development in asthma, COPD and other respiratory diseases. Their main activities are summarised opposite: Research Advanced human in vitro models generated from the BioBank samples, including use of virus infection models (experienced in use of rhinovirus, RSV, influenza etc.) Lung biomarker validation and assessment Application of human tissue models for: Target discovery Target validity Support clinical activity Clinical Extensive BioBank of relevant tissue, cells, blood and airway secretions from volunteers (both diseased and healthy) Phase I &II trial capability in respiratory patients during naturally acquired cold infections For more detailed information please go to Technology and Programmes Synairgen plc Registered in England and Wales No. 5233429 Registered office Mailpoint 810, Level F, South Block, Southampton General Hospital, Tremona Road, Southampton, SO16 6YD, UK